New insights into CD4+ T cell abnormalities in systemic sclerosis

Cytokine and Growth Factor Reviews

Volumn 28, Issue , 2016, Pages 31-36

  Liu, Mengguo ^a,b   Wu, Wenyu ^a   Sun, Xinfen ^a   Yang, Ji ^b   Xu, Jinhua ^a   Fu, Wenwen ^a   Li, Ming ^b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Systemic Sclerosis; Th17 cells; Th22 cells; Th9 cells; Treg cells

Indexed keywords

AUTOIMMUNITY; CD4+ T LYMPHOCYTE; FIBROSIS; HELPER CELL; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC SCLEROSIS; T FOLLICULAR HELPER CELL; TH22 CELL; TH9 CELL; ANIMAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; TH17 CELL;

CYTOKINE; INTERLEUKIN 17;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; HUMANS; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84951852127     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.12.002     Document Type: Review

References (74)

1. Pattanaik D., Brown M., Postlethwaite B.C., Postlethwaite A.E. Pathogenesis of systemic sclerosis. Front. Immunol. 2015, 6(272).
2. Katsumoto T.R., Whitfield M.L., Connolly M.K. The pathogenesis of systemic sclerosis. Annu. Rev. Pathol. 2011, 6:509-537.
3. van den Hoogen F., Khanna D., Fransen J., et al. classification criteria for systemic sclerosis: an American College of Rheumatology/European league against Rheumatism collaborative initiative. Arthritis Rheum. 2013, 65:2737-2747.
4. van den Hoogen F., Khanna D., Fransen J., et al. classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 2013, 72:1747-1755.
5. Guiducci S., Distler O., Distler J.H., Matucci-Cerinic M. Mechanisms of vascular damage in SSc-implications for vascular treatment strategies. Rheumatology (Oxford) 2008, 47(Suppl. 5):v18-v20.
6. Motegi S., Okada E., Uchiyama A., et al. Role of endothelin-1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis. Exp. Dermatol. 2014, 23:664-669.
7. Matucci-Cerinic M., Kahaleh B., Wigley F.M. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013, 65:1953-1962.
8. Kavian N., Batteux F. Macro- and microvascular disease in systemic sclerosis. Vascul. Pharmacol. 2015.
9. Bhattacharyya S., Wei J., Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat. Rev. Rheumatol. 2012, 8:42-54.
10. Manno R., Boin F. Immunotherapy of systemic sclerosis. Immunotherapy 2010, 2:863-878.
11. Cipriani P., Fulminis A., Pingiotti E., et al. Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis. J. Rheumatol. 2006, 33:2003-2014.
12. Roumm A.D., Whiteside T.L., Medsger T.J., Rodnan G.P. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984, 27:645-653.
13. Truchetet M.E., Brembilla N.C., Montanari E., Allanore Y., Chizzolini C. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res. Ther. 2011, 13:R166.
14. Gu Y.S., Kong J., Cheema G.S., Keen C.L., Wick G., Gershwin M.E. The immunobiology of systemic sclerosis. Semin. Arthritis Rheum. 2008, 38:132-160.
15. Kahaleh M.B., Fan P.S., Otsuka T. Gammadelta receptor bearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. Clin. Immunol. 1999, 91:188-195.
16. Scharffetter K., Lankat-Buttgereit B., Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur. J. Clin. Invest. 1988, 18:9-17.
17. Parel Y., Aurrand-Lions M., Scheja A., Dayer J.M., Roosnek E., Chizzolini C. Presence of CD4+ CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum. 2007, 56:3459-3467.
18. De Palma R., Del G.F., Lupoli S., Altucci P., Abbate G., Valentini G. Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin. Clin. Exp. Immunol. 2006, 144:169-176.
19. Grassegger A., Pohla-Gubo G., Frauscher M., Hintner H. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesisantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis. Wien Med. Wochenschr. 2008, 158:19-28.
20. Jiang N., Li M., Zeng X. Correlation of Th17 cells and CD4(+)CD25(+) regulatory T cells with clinical parameters in patients with systemic sclerosis. Chin. Med. J. (Engl.) 2014, 127:3557-3561.
21. Antiga E., Quaglino P., Bellandi S., et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br. J. Dermatol. 2010, 162:1056-1063.
22. Klein S., Kretz C.C., Ruland V., et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann. Rheum. Dis. 2011, 70:1475-1481.
23. Szodoray P., Nakken B., Barath S., et al. Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders. Hum. Immunol. 2013, 74:1510-1518.
24. Papp G., Horvath I.F., Barath S., et al. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand. J. Rheumatol. 2011, 40:205-210.
25. Fenoglio D., Battaglia F., Parodi A., et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin. Immunol. 2011, 139:249-257.
26. Antiga E., Quaglino P., Bellandi S., et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br. J. Dermatol. 2010, 162:1056-1063.
27. Klein S., Kretz C.C., Krammer P.H., Kuhn A. CD127(low/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood. J. Invest. Dermatol. 2010, 130:492-499.
28. Radstake T.R., van Bon L., Broen J., et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One 2009, 4:e5981.
29. Valmori D., Raffin C., Raimbaud I., Ayyoub M. Human RORgammat+ TH17 cells preferentially differentiate from naive FOXP3 + Treg in the presence of lineage-specific polarizing factors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19402-19407.
30. Zambrano-Zaragoza J.F., Romo-Martinez E.J., Duran-Avelar M.J., Garcia-Magallanes N., Vibanco-Perez N. Th17 cells in autoimmune and infectious diseases. Int. J. Inflam. 2014, 2014:651503.
31. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17Cells. Annu. Rev. Immunol. 2009, 27:485-517.
32. Singh R.P., Hasan S., Sharma S., et al. Th17 cells in inflammation and autoimmunity. Autoimmun. Rev. 2014, 13:1174-1181.
33. Kurasawa K., Hirose K., Sano H., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum. 2000, 43:2455-2463.
34. Xing X., Yang J., Yang X., et al. IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS One 2013, 8:e85032.
35. Rodriguez-Reyna T.S., Furuzawa-Carballeda J., Cabiedes J., et al. Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol. Int. 2012, 32:2653-2660.
36. Radstake T.R., van Bon L., Broen J., et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009, 4:e5903.
37. Murata M., Fujimoto M., Matsushita T., et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?. J. Dermatol. Sci. 2008, 50:240-242.
38. Yang X., Yang J., Xing X., Wan L., Li M. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res. Ther. 2014, 16:R4.
39. Radstake T.R., van Bon L., Broen J., et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009, 4:e5903.
40. Wurster A.L., Rodgers V.L., Satoskar A.R., et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J. Exp. Med. 2002, 196:969-977.
41. Yoshizaki A., Yanaba K., Iwata Y., et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J. Immunol. 2010, 185:2502-2515.
42. Liu M., Yang J., Xing X., Cui X., Li M. Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway. Arthritis Res. Ther. 2014, 16:4223.
43. Liu M., Yang J., Li M. Tanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway. Clinics (Sao Paulo) 2015, 70:250-256.
44. Okamoto Y., Hasegawa M., Matsushita T., et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum. 2012, 64:3726-3735.
45. Fossiez F., Djossou O., Chomarat P., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 1996, 183:2593-2603.
46. Yao Z., Painter S.L., Fanslow W.C., et al. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 1995, 155:5483-5486.
47. Kurasawa K., Hirose K., Sano H., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum. 2000, 43:2455-2463.
48. Brembilla N.C., Chizzolini C. T cell abnormalities in systemic sclerosis with a focus on Th17 cells. Eur. Cytokine Netw. 2012, 23:128-139.
49. Farahani R., Sherkat R., Hakemi M.G., Eskandari N., Yazdani R. Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthmakines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma. Adv. Biomed. Res. 2014, 3:127.
50. Lo R.S., Lison D., Huaux F. CD4+ T lymphocytes in lung fibrosis: diverse subsets, diverse functions T lymphocytes in lung fibrosis: diverse subsets, diverse functions. J. Leukoc. Biol. 2013, 93:499-510.
51. Jager A., Dardalhon V., Sobel R.A., Bettelli E., Kuchroo V.K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 2009, 183:7169-7177.
52. Leng R.X., Pan H.F., Ye D.Q., Xu Y. Potential roles of IL-9 in the pathogenesis of systemic lupus erythematosus. Am. J. Clin. Exp. Immunol. 2012, 1:28-32.
53. Veldhoen M., Uyttenhove C., van Snick J., et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 2008, 9:1341-1346.
54. Dardalhon V., Awasthi A., Kwon H., et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat. Immunol. 2008, 9:1347-1355.
55. Yanaba K., Yoshizaki A., Asano Y., Kadono T., Sato S. Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis. J. Rheumatol. 2011, 38:2193-2197.
56. Eyerich S., Eyerich K., Pennino D., et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Invest. 2009, 119:3573-3585.
57. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H) 1 and T(H) 2 cells. Nat. Immunol. 2009, 10:864-871.
58. Zhang N., Pan H.F., Ye D.Q. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol. Cell Biochem. 2011, 353:41-46.
59. Sugita S., Kawazoe Y., Imai A., et al. Role of IL-22- and TNF-alpha-producing Th22 cells in uveitis patients with Behcet's disease. J. Immunol. 2013, 190:5799-5808.
60. Mathian A., Parizot C., Dorgham K., et al. Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann. Rheum. Dis. 2012, 71:1227-1234.
61. Brembilla N.C., Dufour A.M., Alvarez M., et al. IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Ann. Rheum. Dis. 2015.
62. Breitfeld D., Ohl L., Kremmer E., et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 2000, 192:1545-1552.
63. Schaerli P., Willimann K., Lang A.B., Lipp M., Loetscher P., Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 2000, 192:1553-1562.
64. Simpson N., Gatenby P.A., Wilson A., et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 2010, 62:234-244.
65. Zhang X., Lindwall E., Gauthier C., et al. Circulating CXCR5+ CD4+ helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production. Lupus 2015.
66. Ma C.S., Deenick E.K. Human T follicular helper (Tfh) cells and diseasen T follicular helper (Tfh) cells and disease. Immunol. Cell Biol. 2014, 92:64-71.
67. Morita R., Schmitt N., Bentebibel S.E., et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011, 34:108-121.
68. Ma J., Zhu C., Ma B., et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin. Dev. Immunol. 2012, 2012:827480.
69. Choi J.Y., Ho J.H., Pasoto S.G., et al. Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity. Arthritis Rheumatol. 2015, 67:988-999.
70. Morita R., Schmitt N., Bentebibel S.E., et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011, 34:108-121.
71. Li X.Y., Wu Z.B., Ding J., et al. Role of the frequency of blood CD4(+) CXCR5(+) CCR6(+) T cells in autoimmunity in patients with Sjogren's syndrome. Biochem. Biophys. Res. Commun. 2012, 422:238-244.
72. Liu R., Wu Q., Su D., et al. A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. Arthritis Res. Ther. 2012, 14:R255.
73. Ma J., Zhu C., Ma B., et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin. Dev. Immunol. 2012, 2012:827480.
74. Wang J., Shan Y., Jiang Z., et al. High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin. Exp. Immunol. 2013, 174:212-220.